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Abstract The protein GM, which targets protein phosphatase 1
(PP1) to the glycogen particles and sarcoplasmic reticulum (SR)
of striated muscles, is known to be phosphorylated at Ser48 and
Ser67 in vitro by adenosine 3P,5P cyclic monophosphate-
dependent protein kinase (PKA) and at Ser48 by MAP kinase-
activated protein kinase-1 (MAPKAP-K1, also called p90 RSK).
The phosphorylation of Ser48 increases the rate at which the
glycogen-associated PP1.GM complex dephosphorylates (acti-
vates) glycogen synthase, but the phosphorylation of Ser67 has
the opposite effect, suppressing the activity of PP1 toward
glycogen-bound substrates. The phosphorylation of Ser67 over-
rides the activating effect of Ser48 phosphorylation because it
dissociates PP1 from GM. Here, we use two phospho-specific
antibodies to demonstrate that the SR-associated form of GM, as
well as the glycogen-associated form of GM, becomes phos-
phorylated at Ser48 and Ser67 in response to adrenaline,
supporting the view that the PKA-mediated regulation of the
PP1.GM complex plays a role in the adrenergic control of
glycogen metabolism and SR function. In contrast, Ser48 is not
phosphorylated significantly in response to insulin, and neither is
Ser67. Thus the phosphorylation of GM at Ser48 by MAPKAP-
K1 or other insulin-stimulated protein kinases is not involved in
the activation of glycogen synthase by insulin.
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1. Introduction
Protein phosphatase 1 (PP1) is a serine/threonine-speci¢c
phosphatase involved in the regulation of numerous cellular
processes. This diversity is achieved by the interaction of the
catalytic subunit with more than 20 distinct targetting sub-
units, which localise it to speci¢c subcellular sites, modulate
its substrate speci¢city and allow its activity to be regulated
by extracellular signals [1^3]. A targetting subunit known as
GM plays a dual role in directing PP1 to both the glycogen
particles [4] and the sarcoplasmic reticulum (SR) of striated
muscles [5]. The PP1-binding domain is near the N-terminus
of GM [2], followed by the glycogen-binding domain [6], the
SR-binding domain being positioned near the C-terminus of
this 124 kDa protein [7] (Fig. 1).
Two serine residues located at positions 48 and 67 of the
rabbit muscle protein [7] are phosphorylated by adenosine
3P,5P cyclic monophosphate (cAMP)-dependent protein kinase
(PKA) in vitro [8]. Ser67 is located in the PP1-binding motif
[2] and its phosphorylation disrupts the interaction of PP1
with GM and hence releases it from glycogen [8] and SR
membranes [5]. Since the binding of GM to PP1 enhances
the activity of the phosphatase towards glycogen-bound sub-
strates (glycogen phosphorylase and glycogen synthase) the
phosphorylation of GM at Ser67 provides a potential mecha-
nism for selectively inhibiting the dephosphorylation of these
enzymes [9]. In contrast, the phosphorylation of Ser48 in-
creases the rate at which the glycogen-associated PP1.GM
complex dephosphorylates (activates) glycogen synthase [10],
but activation is overridden by the phosphorylation of Ser67
since it dissociates PP1 from GM.
The hormone adrenaline, which elevates cAMP and acti-
vates PKA in skeletal muscle, induces the phosphorylation
of glycogen-associated GM at Ser48 and Ser67 when injected
intravenously into rabbits [11] and releases PP1 from GM [12].
This indicates that the PKA-catalysed phosphorylation of GM
is indeed an in vivo mechanism for regulating the activity of
glycogen phosphorylase and glycogen synthase in response to
adrenaline. However, in these studies, the level of phosphor-
ylation of Ser48 appeared to be high, even in the absence of
adrenergic stimulation [11,13], raising the possibility that
Ser48 is also phosphorylated by another protein kinase in
vivo. The phosphorylation state of SR-bound GM was not
analysed in these studies.
A protein kinase that is activated in vivo by mitogen-acti-
vated protein kinase (MAPK), and therefore termed MAPK-
activated protein kinase-1 (MAPKAP-K1, also called p90
RSK), was found to phosphorylate GM at Ser48 much more
rapidly than at Ser67 and hence increased the glycogen syn-
thase phosphatase activity of PP1.GM in vitro [12^15]. Insulin
is known to activate MAPKAP-K1 [10,16] and was reported
to increase the phosphorylation of GM at Ser48 in rabbit
skeletal muscle [10]. This suggested that the MAPKAP-K1-
catalysed phosphorylation of Ser48 might be a mechanism by
which insulin stimulated PP1.GM and hence the activation of
glycogen synthase in vivo.
Several lines of evidence obtained subsequently have cast
doubt on the hypothesis discussed above. Firstly epidermal
growth factor, a stronger activator of the MAPK cascade
than insulin, does not mimic a number of the actions of in-
sulin in primary adipocytes, including the stimulation of gly-
cogen synthase [17]. Secondly, in mice that overexpress a mu-
tant insulin receptor with severely impaired function, insulin
no longer activates the MAPK cascade but still triggers the
activation of glycogen synthase [16]. Thirdly, PD 98059, a
drug that blocks activation of the MAPK cascade and hence
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the activation of MAPKAP-K1 [18], does not prevent the
insulin-induced activation of glycogen synthase in adipocytes
or L6 myotubes, a skeletal muscle cell line [19].
For these reasons, we decided to reinvestigate the phos-
phorylation of GM at Ser48 and Ser67 in adult skeletal muscle
using improved methodology. By generating antibodies that
recognise GM only when it is phosphorylated at Ser48 or
Ser67, we have established that adrenaline stimulates the
phosphorylation of SR-bound as well as glycogen-bound
GM, while insulin fails to trigger the phosphorylation of either
site under conditions where it stimulates the activation of
glycogen synthase.
2. Materials and methods
2.1. Materials
A glutathione S-transferase fusion protein encoding the ¢rst 243
residues of human GM (GST-GM[2^243]) [20] was expressed in Es-
cherichia coli and puri¢ed by glutathione-Sepharose chromatography
(Dr G. Moorhead) and PKA was puri¢ed from bovine muscle [21]
(Dr C. Smythe) in this Unit by the investigators shown in parentheses.
The peptides SPQPSRRGS*GSSED (corresponding to residues 40^53
of mouse GM) and SASRRVS*FADSLG (corresponding to residues
61^73 of mouse GM), where S* represents a phosphoserine residue,
and the corresponding dephosphorylated peptides were synthesised by
Dr G. Blomberg (Department of Biochemistry, University of Bristol,
UK). Nitrocellulose was purchased from Schleicher and Schuell (An-
derman and Co. Ltd, Surrey, UK), CH-Sepharose and the Enhanced
Chemiluminescence immunoblotting kit from Amersham Pharmacia
GB Ltd (Amersham, UK) and adrenaline from Sigma (Poole, UK).
‘Complete’ protease inhibitor tablets were obtained from Boehringer
Mannheim (Lewes, UK) and rabbit anti-sheep IgG conjugated to
horseradish peroxidase from Pierce (Chester, UK).
2.2. Production of anti-GM antibodies
Antisera were raised in sheep against PP1.GM puri¢ed from rabbit
skeletal muscle in which the phosphatase catalytic subunit is com-
plexed to a 103 kDa proteolytic fragment of GM [13] and a⁄nity
puri¢ed by chromatography on a CH-Sepharose column coupled to
GST-GM[2^243]. This antibody recognises dephosphorylated and
phosphorylated GM equally well.
In order to raise antibodies that speci¢cally recognise GM phos-
phorylated at either Ser48 or Ser67, the peptides SPQPSRR-
GS*GSSED and SASRRVS*FADSLG, corresponding to residues
40^53 and 61^73 of mouse GM, respectively, were each conjugated
separately to both bovine serum albumin and keyhole limpet haemo-
cyanin and the conjugates injected into sheep at the Scottish Antibody
Production Unit (Carluke, UK). The antibodies were puri¢ed from
the antisera by chromatography on peptide-CH-Sepharose columns.
The sera were ¢rst applied to the relevant dephosphopeptide Sephar-
ose (to remove any antibodies that recognised dephosphorylated GM)
and the £owthrough fractions applied to the relevant phosphopeptide
Sepharose. Antibodies that recognise GM phosphorylated at Ser48 or
Ser67 were eluted with 50 mM glycine^HCl pH 2.5, neutralised by
making the solution 0.2 M in Tris^HCl pH 8.0 and stored frozen in
aliquots at 320‡C.
2.3. Phosphorylation of GST-GM [2^243] with PKA
The incubations (0.25 ml) were carried out for 1 h at 30‡C and
comprised GST-GM[2^243] (5 Wg), PKA (50 U/ml), 50 mM Tris^
HCl, pH 7.5, 0.1 mM EGTA, 0.1% 2-mercaptoethanol, 10 mM
Mg(CH3COO)2 and 0.1 mM ATP. The reactions were terminated
by the addition of 0.2 vol of 62.5 mM Tris^HCl, pH 6.8, 10% SDS,
50% glycerol, 0.005% (m/v) bromophenol blue, 5% (v/v) 2-mercapto-
ethanol.
2.4. Preparation of rat skeletal muscle extracts
Adult male Wistar rats were anaesthetised by an intraperitoneal
injection of sodium pentobarbital. The saphenous vein of one hind
limb was exposed and injected with either 3 mg/kg propranolol, 3 mg/
kg propranolol+1 U/kg insulin or 12 Wg/kg adrenaline. After 5 min
(propranolol or propranolol+insulin) or 30 s (adrenaline) the muscle
from the limb that had not been injected was freeze-clamped in situ
between aluminium tongs precooled to the temperature of liquid ni-
trogen and removed from the animal, which was then killed immedi-
ately. The frozen muscle was powdered ¢nely under liquid nitrogen
using a pestle and mortar, then homogenised at 4‡C in 3 vol of ice-
cold homogenisation bu¡er (25 mM Tris^HCl, pH 7.5, 50 mM NaF,
2 mM EDTA, 2 mM EGTA, 1 mM sodium orthovanadate, 1 WM
microcystin-LR, 0.1% (v/v) 2-mercaptoethanol and ‘Complete’ pro-
tease inhibitor cocktail [one tablet per 25 ml]). The homogenates
were centrifuged at 13 000Ug for 5 min at 4‡C and the supernatants
(cytosol) were snap-frozen and stored at 380‡C until use. The myo¢-
brillar pellets were washed twice in 2 vol of homogenisation bu¡er
and then rehomogenised in 2 vol of the same bu¡er containing 1%
(v/v) Triton X-100 in order to solubilise the SR membranes. The
homogenates were again centrifuged at 13 000Ug for 5 min at 4‡C
and the supernatants (containing the SR-associated PP1.GM complex)
snap-frozen and stored at 380‡C until use.
2.5. Immunoblotting
Protein samples were separated by electrophoresis on 10% SDS/
polyacrylamide gels and transferred to nitrocellulose membranes.
Non-speci¢c binding was blocked by incubation for 2 h in bu¡er A
(100 mM Tris^HCl, pH 7.5, 150 mM NaCl, 0.2% (v/v) Tween-20) and
5% (m/v) dried milk powder. The membranes were then incubated for
1 h with primary antibody diluted in bu¡er A plus 5% (m/v) dried
milk powder, washed 5^6 times over the space of 1 h with bu¡er A,
and incubated for 1 h with anti-sheep IgG coupled to horseradish
peroxidase (0.1 Wg/ml) in bu¡er A plus 5% (m/v) dried milk powder.
Finally the membranes were washed 5^6 times over the space of 1 h
with bu¡er A and immunoreactive bands visualised using the en-
hanced chemiluminescence (ECL) system.
2.6. Immunoprecipitation assay of protein kinase B
Protein kinase BK (PKBK) was immunoprecipitated from control
and insulin-stimulated muscle extracts as described [22,23].
3. Results
3.1. Production of antibodies that recognise GM phosphorylated
at Ser48 or Ser67
Skeletal muscle has a low permeability to inorganic phos-
phate, making it di⁄cult to 32P-label intracellular proteins to
a high speci¢c radioactivity, especially low abundance pro-
teins like GM whose intracellular concentration is 6 1 WM
[4]. Phospho-speci¢c antibodies were therefore raised that rec-
ognise GM only when it is phosphorylated at Ser48 or Ser67.
These antibodies recognised bacterially expressed human
GST-GM[2^243] that had been phosphorylated with PKA,
but did not recognise dephosphorylated GM (Fig. 2). The
reactivity of the phospho-speci¢c Ser48 antibody could be
blocked by pre-incubation with the appropriate phosphopep-
tide immunogen, but not with the corresponding dephos-
phorylated peptide (Fig. 2) or the phosphopeptide corre-
sponding to the sequence surrounding Ser67 (data no
shown). Similarly the reactivity of the phospho-speci¢c
Ser67 antibody could be blocked by pre-incubation with the
appropriate phosphopeptide immunogen, but not with the
corresponding dephosphorylated peptide (Fig. 2) or the phos-
phopeptide corresponding to the sequence surrounding Ser48
(data not shown). In contrast, another antibody raised against
a 103 kDa proteolytic fragment of rabbit GM recognised both
the dephosphorylated and phosphorylated forms of GM with
equal e⁄ciency (Fig. 2A).
3.2. GM becomes phosphorylated in vivo at Ser48 and Ser67 in
response to adrenaline, but not insulin
Adrenaline, acting via cAMP and PKA, is known to trigger
the activation of glycogen phosphorylase and inactivation of
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glycogen synthase within 1 min (reviewed in [24]). If the phos-
phorylation of GM plays a role in the adrenergic control of
glycogen metabolism, it would therefore have to occur in the
same time frame. Using the phospho-speci¢c antibodies char-
acterised above, we found that adrenaline induced a large
increase in the phosphorylation of GM at both Ser48 and
Ser67 after 30 s in rat skeletal muscle (Fig. 3A).
The results presented in Fig. 3 were carried out using skel-
etal muscle cytosol, which contains the glycogen-associated
form of GM, but not SR-bound GM which is pelleted with
the myo¢brils. We therefore also examined the e¡ect of adren-
aline on the phosphorylation of SR-bound GM which can be
released from the myo¢brils by extraction with Triton X-100
[5]. These studies showed that adrenaline also increases the
phosphorylation of SR-bound GM at Ser48 and Ser67 within
30 s in rat skeletal muscle (Fig. 3B).
Insulin induces the dephosphorylation and activation of
glycogen synthase in skeletal muscle. This occurs with a half
time of less than 5 min, is maximal after 15 min [23] and
results from the dephosphorylation of three serine residues
that are phosphorylated by glycogen synthase kinase-3
(GSK3) [25] and dephosphorylated by PP1.GM [9]. If the
phosphorylation of GM at Ser48 plays a role in the stimula-
tion of glycogen metabolism it should therefore occur in the
same time scale. However, immunoblotting failed to detect a
signi¢cant increase in the phosphorylation of Ser48 after stim-
ulation for 5 min (Fig. 3A) or 15 min (data not shown) with
insulin. Insulin stimulation also had no e¡ect on the phos-
phorylation of Ser67 under the conditions studied (Fig. 3A).
In contrast, insulin increased the speci¢c activity of PKBK
from 0.4 þ 0.1 mU/mg to 6.2 þ 0.4 mU/mg and 4.6 þ 0.4 mU/
mg after 5 and 15 min, respectively (average of results from
two experiments), similar to results reported previously [23].
4. Discussion
In this paper we use improved methodology to establish
that adrenaline triggers an extremely rapid phosphorylation
of glycogen-associated GM at Ser48 and Ser67 in rat skeletal
muscle (Fig. 3A). We also demonstrate for the ¢rst time that
SR-associated GM becomes phosphorylated at these two ser-
ine residues during adrenergic stimulation (Fig. 3B). The role
of SR-associated PP1.GM in skeletal muscle is unclear. How-
ever, in cardiac muscle GM and the integral SR-membrane
protein phospholamban may interact via their transmembrane
domains [26] and biochemical evidence suggests that PP1.GM
may be the major phospholamban phosphatase in the heart
[27]. Phospholamban suppresses the activity of the cardiac SR
calcium pump, which is relieved by the PKA-catalysed phos-
phorylation of phospholamban at Ser16 and the calmodulin-
dependent protein kinase II-catalysed phosphorylation of
Fig. 1. Domain structure of GM. The PP1-binding, glycogen-binding
and SR-binding domains are indicated. The sequences of the phos-
phopeptides used to raise the phospho-speci¢c antibodies that recog-
nise GM phosphorylated at Ser48 or Ser67 are also shown, with the
phosphoserine residues marked with asterisks. Ser67 is located in
the PP1-binding domain, and Ser48 N-terminal to it. Sequences re-
fer to murine GM.
Fig. 2. Characterisation of antibodies that speci¢cally recognise GM
phosphorylated at Ser48 or Ser67. 100 ng of unphosphorylated
GST-GM[2^243] (upGM) or PKA-phosphorylated GST-GM[2^243]
(pGM) were subjected to SDS-polyacrylamide gel electrophoresis
and transferred to nitrocellulose. Immunoblotting was carried out
using 3 Wg/ml of an antibody raised against the peptide SPQPSRR-
GS*GSSED (anti-pGM(Ser48)), 3 Wg/ml of an antibody raised
against the peptide SASRRVS*FADSLG (anti-pGM(Ser67)) or
0.5 Wg/ml of an antibody raised against the 103 kDa proteolytic
fragment of GM (anti-GM). Where indicated, the anti-pGM(Ser48)
antibody was incubated for 1 h at ambient temperature with 1 mM
of the phosphopeptide SPQPSRRGS*GSSED (pSer48-peptide) or
the dephosphopeptide (Ser48-peptide) prior to immunoblotting. Sim-
ilarly, the anti-pGM(Ser67) antibody was incubated, where indicated,
with the phosphopeptide SASRRVS*FADSLG (pSer67-peptide) or
the dephosphopeptide (Ser67-peptide) prior to immunoblotting.
Fig. 3. Phosphorylation of GM in response to adrenaline, but not
insulin. Cytosolic fractions (A) or Triton X-100 extracts of myo¢-
brils (B) were prepared from the hindlimb skeletal muscle of rats in-
jected with propranolol (Pro), propranolol+insulin (Ins) or adrena-
line (Adr) as described in Section 2. Cytosol (0.5 mg protein) or
Triton extract (75 Wg protein) was subjected to SDS-polyacrylamide
gel electrophoresis and transferred to nitrocellulose. Immunoblotting
was carried out using the anti-pGM(Ser48), anti-pGM(Ser67) and
anti-GM antibodies, as described in the legend to Fig. 2.
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Thr17. This appears to be a major mechanism by which
adrenaline stimulates the rate and force of cardiac muscle
contraction [28,29].
The phosphorylation of Ser67 is known to trigger the dis-
sociation of PP1 from GM, leading to the release of the PP1
catalytic subunit from the SR membrane [5] as well as the
glycogen particles [8,12]. It may therefore contribute to the
adrenaline-induced phosphorylation of phospholamban at
Ser16 and Thr17, as well as the activation of glycogen phos-
phorylase and the inhibition of glycogen synthase.
GM is phosphorylated at Ser48 by PKA in vitro at a similar
rate to Ser67 [8], but Ser48 is dephosphorylated much more
slowly in vitro by the major protein phosphatases PP1, PP2A
or PP2B [8]. As a result, a form of GM is generated that is
phosphorylated relatively speci¢cally at Ser48. Interestingly,
the PP1.GM complex in which GM is phosphorylated speci¢-
cally at Ser48 is 2^3-fold more active than unphosphorylated
PP1.GM in dephosphorylating glycogen synthase [10]. If Ser67
is dephosphorylated more rapidly than Ser48 in vivo, as it is
in vitro, this could provide a potential mechanism for enhanc-
ing the rate of reactivation of glycogen synthase and hence the
resynthesis of glycogen, as well as the dephosphorylation of
phospholamban, in the recovery period after adrenergic stim-
ulation ceases.
In earlier studies, we reported that the level of phosphor-
ylation of Ser48 was very high (0.5^0.75 mol/mol) in rabbit
skeletal muscle, even in the absence of adrenaline [11,13],
which was not observed in the present study. The high level
found in earlier studies is likely to be artefactual and probably
explained by the failure to employ freeze-clamping procedures
in these experiments. It seems likely that, in our earlier study,
Ser48 was phosphorylated post mortem by a protein kinase(s)
activated by the contraction of the muscle that occurred dur-
ing its excision.
The acute insulin-induced activation of glycogen synthase
in skeletal muscle results mainly from the dephosphorylation
of serine residues that are phosphorylated by GSK3 [25] and
thought to be dephosphorylated by PP1.GM. This indicates
that the action of insulin is likely to be mediated via an in-
hibition of GSK3 and/or an activation of PP1.GM. It is now
well established that insulin does indeed trigger an inhibition
of GSK3 via a PI 3-kinase-dependent protein kinase cascade
that has been dissected over the past few years (reviewed in
[30]). This inhibition of GSK3 is likely to contribute to the
insulin-induced activation of glycogen synthase, but the pos-
sibility that insulin also stimulates a glycogen synthase phos-
phatase is not excluded. In the present study, using improved
methodology, we failed to con¢rm our original report that
insulin induces the phosphorylation of GM at Ser48 [10],
which would be expected to activate PP1.GM (see Section
1). However, it remains possible that insulin activates
PP1.GM by another mechanism; for example by stimulating
the phosphorylation of another site on GM. Moreover, two
other glycogen-associated forms of PP1 have subsequently
been identi¢ed in skeletal muscle in which PP1 is complexed
to homologues of GM, termed R5 (or PTG) [31,32] and R6
[33]. Although present at much lower concentrations than
PP1.GM in adult mammalian skeletal muscle (G. Browne, P.
Cohen and P.T.W. Cohen, unpublished work), the possibility
that insulin promotes the dephosphorylation of glycogen syn-
thase by activating PP1.R5 or PP1.R6 remains a possibility.
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